Our networking is well underway with investors and potential strategic partners for the #JPM2024 and we invite you to meet Lu Alleruzzo at JPM Healthcare Conference, Theresa Visarius at JPM Biotech Showcase, and Tomas Hode at RESI, in San Francisco January 8 -12, 2023.

Immunophotonics co-founders Lu Alleruzzo (CEO) and Tomas Hode, PhD (CIO and President) are looking forward to attending Spectrum Conference, January 11 – 14, 2024 in Miami, Florida. #interventionaloncology #ablation #immunooncology #cancer #Immunophotonics #SPECTRUM2024

Tomas Hode, PhD, Co-Founder, CIO, and President at Immunophotonics, Inc. will be attending the #SIO2024 Annual Scientific Meeting January 26 - 29, in Long Beach, CA. #interventionaloncology #ablation #immunooncology #cancer #immunotherapy #Immunophotonics #innovation

Cancer doesn’t mean the end of life. So, never give up. Keep fighting! To all the fighters and cancer survivors on World Cancer Day, Immunophotonics is fighting with you. #WorldCancerDay #CloseTheCareGap #cancer #immunotherapy

Immunophotonics wants to congratulate Professor Wei Chen & his lab at the University of Oklahoma, along with contributors Lu Alleruzzo, Samuel S.K. Lam, & Tomas Hode of Immunophotonics, for their publication in Acta Biomaterialia, an international, journal published by Elsevier.

Immunophotonics is grateful to the National Cancer Institute (NCI) SBIR Investor Initiatives Team for providing us the opportunity to showcase our technology at the Global Life Science Partnering & Investor Conf. presented by BIOcom California taking place Feb 27–29, La Jolla, CA

Immunophotonics is pleased to announce a partnership that will combine use of Immunophotonics’ lead asset, IP-001 & AngioDynamics’ ablation devices to explore the power of ablation in combination with immunotherapy for the treatment of solid tumor cancers.

Immunophotonics is thrilled to be showcased as the Member Highlight for March by The Missouri Biotechnology Association #MOBIO, both on their homepage & in the March newsletter. This recognition underscores Immunophotonics commitment to advancing life science research.

Tomas Hode, PhD, who serves as the Co-Founder, CIO, and President at Immunophotonics, Inc., is eager to attend the AngioDynamics International Life Symposium “The Human Touch, behind Innovation” scheduled for March 21-23 in Rome. #LifeSymposium #immunophotonics #innovation

Tomas Hode, PhD, who serves as the Co-Founder, CIO, & President at Immunophotonics is excited to attend the European Conference on Interventional Oncology (#ECIO2024) in Palma de Mallorca, Spain, from April 28-May 1. #interventionaloncology #ablation #immunooncology #innovati

Immunophotonics, Inc. is delighted to introduce Jacqueline Hess as the newest addition to our advisory board. Ms. Hess has over 25 years of Big 4 experience supporting U.S. biotech companies that are expanding globally, with a particular focus on the U.S.-Swiss business corridor.

Immunophotonics is pleased to announce the appointment of Dr. Maziar Assadi Gehr in the role of Medical Director. Dr. Gehr will spearhead the development of our pivotal trial, drawing upon his extensive expertise in various facets of the drug development process.

Immunophotonics Lu Alleruzzo (CEO) & Tomas Hode, PhD (CIO & President) will be in Chicago at the ASCO annual meeting, May 31-June 3. They are thrilled to engage with clinical experts worldwide, explore cutting-edge research, and discover innovative treatments. #ASCO24

Immunophotonics is excited to share that Dr. Robert CG Martin II, M.D, PhD, will be presenting his IRE data at the Central Surgical Association 81st Annual Meeting on June 6 at 9:10 am in the SCIENTIFIC SESSION I, Medallion Ballroom AB. #interventionaloncology #ablation #cancer

Lu Alleruzzo, CEO, Tomas Hode, PhD, CIO & President, along with the Immunophotonics Team, extend their congratulations to Professor Wei Chen, co-inventor of IP-001, for being honored as one of the Class of 2024 Senior Members by the National Academy of Inventors (NAI) #innovation

Immunophotonics is excited to announce the Cancer Center Amsterdam at Amsterdam UMC received authorization to proceed with recruitment to conduct a clinical trial combining Immunophotonics’ investigational drug IP-001 with AngioDynamics' ablation devices.

Immunophotonics featured in Pharma Tech Outlook magazine. Immunophotonics innovative approach could transform standard treatments into powerful immunotherapies with IP-001 turning every procedure into an opportunity to mobilize the body’s natural immune system against cancer.

Prof. Wei Chen & his team recently organized a session titled “Immunophotonics” for the Gordon Research Conf. Optics & Photonics in Medicine & Biology in Lewiston, ME. Prof. Chen delivered an oral presentation on "Localized Immunophotonics for the Treatment of Metastatic Cancers"

We are thrilled to announce that Dr. Robert Martin has successfully enrolled & treated the 1st patient in our groundbreaking clinical trial: A Randomized Phase 2 Study to Evaluate the Safety and Efficacy of IP-001 as Adjuvant Therapy in Participants with Hepatocellular Carcinoma.

Immunophotonics is thrilled to have won the Startup World Cup St. Louis Regional finals. A big thank you to Emily Hemingway and her team at TechSTL for their hard work in organizing this remarkable event. You did an exceptional job! Silicon Valley here we come!